WSTAP-2025

Dr. Boris Farber, CEO of TRIZ Biopharma Innovations LLC, is the world’s only TRIZ Master in pharmaceutical biotechnology, with four decades of expertise spanning AI, expert systems, and perceptron-based neural networks. Holding dual PhDs and 220+ patents, including US011191806 for a polymyxin-based nephroprotective composition, and more than 500 scientific publications and books, Dr. Farber is a pioneer of Dynamic Drugs and nephroprotectors such as NGL022, addressing the global challenge of antibiotic-induced kidney injury. His TRIZ-guided AI breakthroughs, published in Current Drug Safety and the International Journal of Computational Biology (2024), are revolutionizing drug design and bridging the gap between biotechnology and toxicology. Dr. Farber’s visionary leadership and interdisciplinary approach have earned him global recognition as a thought leader and an inspiring speaker. At WSTAP-2025, he will share actionable insights into AI-driven pharmacology, empowering researchers to enhance drug safety and efficacy. Dr. Artur Martynov, CSO and co-inventor of NGL022, brings deep expertise in molecular dynamics and antimicrobial peptides, further strengthening TRIZ Biopharma’s mission to transform personalized medicine and nephroprotection. Dr. Farber’s vision for the future of medicine is rooted in the synergy between dynamic drug design and artificial intelligence. Dr. Farber’s contributions have earned him membership in nine prestigious scientific academies. He has received numerous accolades, including the Paul Ralph Ehrlich Medal, Otto Heinrich Warburg Medal, Nikola Tesla Gold Medal, and the European Academy for Natural Sciences Award for his advancements in TRIZ-based drug development. These honors reflect his dedication to advancing healthcare through rigorous science and innovative problem-solving. https://www.linkedin.com/in/dr-boris-farber-0309b6121/ https://www.youtube.com/watch?v=c9rfPmncy1U&t=36s&ab_channel=Farber%27sCenter